BKIE - ETF AI Analysis
Top Page
BNY Mellon International Equity ETF (BKIE)
Rating:66Neutral
Price Target:―
Positive Factors
Low Expense Ratio
The fund charges a very low fee, which helps investors keep more of their returns over time.
Broad International Diversification
Holdings spread across many countries such as Japan, the UK, the U.S., and Europe help reduce the impact of weakness in any single market.
Solid Recent Performance
The ETF has shown steady gains over the past month, three months, and year-to-date, indicating positive recent momentum.
Negative Factors
Heavy Financials Exposure
A large portion of the portfolio is in financial stocks, which can make the fund more sensitive to changes in interest rates and banking conditions.
Mixed Results Among Top Holdings
While some leading positions like ASML, Toyota, and Siemens have performed strongly, others such as Nestlé, SAP, and Royal Bank of Canada have been weaker and may drag on returns.
Limited Sector Balance
Compared with its sizable financial and industrial stakes, the fund has relatively smaller allocations to areas like technology and real estate, which may reduce exposure to some growth opportunities.
BKIE vs. SPDR S&P 500 ETF (SPY)
AUM1.04B
RegionDeveloped Markets
Expense Ratio0.04%
Beta0.75
IssuerBNY Mellon
Inception DateApr 22, 2020
Dividend Yield3.46%
Asset ClassEquity
Index TrackedSolactive GBS Developed Markets ex United States Large & Mid Cap Index - Benchmark TR Gross
Share Statistics
EPS (TTM)N/A
Shares OutstandingN/A
10 Day Avg. Volume261,569
30 Day Avg. Volume108,211
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
P/FCF RatioN/A
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
126.92Price Target Upside― Downside
Rating ConsensusModerate Buy
Number of Analyst Covering966
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
BKIE Summary
BKIE is the BNY Mellon International Equity ETF, which tracks the Solactive GBS Developed Markets ex United States Large & Mid Cap Index. It invests in a wide range of companies outside the U.S., across countries like Japan, the UK, and Germany, and sectors such as financials, industrials, and technology. Well-known holdings include ASML, Toyota, Nestlé, and AstraZeneca. Someone might invest in BKIE to diversify beyond the U.S. and tap into long-term growth in global markets with one simple fund. A key risk is that international stocks can be volatile and move differently than the U.S. market.
How much will it cost me?The BNY Mellon International Equity ETF (BKIE) has an expense ratio of 0.04%, which means you’ll pay $0.40 per year for every $1,000 invested. This is lower than average because it’s passively managed, tracking an index rather than relying on active management strategies.
What would affect this ETF?BKIE's focus on developed markets outside the U.S. could benefit from economic recovery in Europe and Asia, as well as growth in sectors like financials and technology, which are heavily weighted in the ETF. However, potential risks include geopolitical tensions, regulatory changes in key regions, or slower-than-expected growth in international markets, which could negatively impact top holdings like ASML and Nestlé. Additionally, currency fluctuations could affect returns for U.S.-based investors.
BKIE Top 10 Holdings
BKIE leans heavily on global blue chips, with Europe doing much of the heavy lifting. ASML has been a key engine over the past few months, even if its recent trading has been a bit choppy, while Shell is clearly rising and giving the fund an energy tailwind. Big pharma names like Novartis and AstraZeneca are more steady than spectacular, helping with stability but not lighting up returns. On the flip side, Roche and several major banks, including HSBC and Royal Bank of Canada, have been lagging and quietly weighing on performance. Overall, it’s a diversified developed-markets ex-U.S. mix, but with noticeable tilts toward financials, health care, and Europe.
Name | Company Name | Weight % | Market Value | Market Cap | Yearly Gain | Overall Rating |
|---|---|---|---|---|---|---|
| ASML Holding NV | 2.16% | $25.08M | €453.65B | 92.32% | 76 Outperform | |
| AstraZeneca | 1.22% | $14.22M | $308.91B | 33.79% | 80 Outperform | |
| Novartis AG | 1.22% | $14.20M | CHF224.37B | 26.94% | 80 Outperform | |
| Roche Holding AG | 1.18% | $13.75M | $319.34B | 22.67% | 73 Outperform | |
| HSBC Holdings | 1.18% | $13.70M | £221.08B | 45.71% | 80 Outperform | |
| Shell (UK) | 1.13% | $13.18M | £193.41B | 23.87% | 73 Outperform | |
| Nestlé SA | 1.06% | $12.32M | CHF198.27B | -3.88% | 71 Outperform | |
| Toyota Motor | 0.96% | $11.19M | ¥43.15T | 25.87% | 80 Outperform | |
| Royal Bank Of Canada | 0.95% | $11.08M | $228.12B | 42.45% | 75 Outperform | |
| Commonwealth Bank of Australia | 0.86% | $9.97M | AU$287.38B | 11.03% | 64 Neutral |
BKIE Technical Analysis
Positive
―
Price Trends
95.87
Negative
93.35
Positive
89.34
Positive
Market Momentum
-1.04
Negative
50.89
Neutral
75.39
Neutral
Evaluating momentum and price trends is crucial in ETF analysis to make informed investment decisions. For BKIE, the sentiment is Positive. The current price of undefined is equal to the 20-day moving average (MA) of 92.62, equal to the 50-day MA of 95.87, and equal to the 200-day MA of 89.34, indicating a neutral trend. The MACD of -1.04 indicates Negative momentum. The RSI at 50.89 is Neutral, neither overbought nor oversold. The STOCH value of 75.39 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for BKIE.
BKIE Peer Comparison
Comparison Results
Performance Comparison
BKIE
BNY Mellon International Equity ETF
93.82
26.89
40.18%
GSIE
Goldman Sachs ActiveBeta International Equity ETF
―
―
―
LVHI
Legg Mason International Low Volatility High Dividend ETF
―
―
―
IMTM
iShares MSCI Intl Momentum Factor ETF
―
―
―
IDMO
Invesco S&P International Developed Momentum ETF
―
―
―
INTF
iShares MSCI Intl Multifactor ETF
―
―
―
Glossary
BuyAn ETF rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the ETF is likely to deliver higher returns compared to other ETFs in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldAn ETF rated as a "Hold" s expected to perform in line with the overall market or a specific benchmark. This rating indicates that the ETF is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellAn ETF rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the ETF may deliver lower returns compared to other ETFs in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
DisclaimerThis AI Analyst ETF Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in ETFs carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.Date of analysis: ―
Table of Contents